Analysed CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) News Sources
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
27-01-2026
yahoo.com
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
14-02-2026
yahoo.com
CSPC Pharmaceutical Group (SEHK:1093) Reports Encouraging SYS6002 Data, Is The Valuation Gap Still Open?
15-10-2026
yahoo.com
What is the current price of CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS)?
The current price of CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) is $3.94.
CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) since the previous trading day is $-0.173.
CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) since the previous trading day is -4.2062%.
What is the most recent average sentiment score for CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS)?
The most recent average sentiment score for CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) is 58 out of 100.
What is the most recent average sentiment for CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS)?
The most recent sentiment for CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS) is .
SEC-8K** Filing Available For CSPC PHARMACEUTICAL-UNSPOADR (CSPCY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.